Clinical bottom line
Tumor Mutational Burden (TMB) is emerging as a potential biomarker for predicting response to immunotherapy, particularly immune checkpoint inhibitors, in various cancers. High TMB may correlate with better treatment outcomes, but its clinical utility is still under investigation. Current evidence suggests that TMB could help identify patients more likely to benefit from immunotherapy, although it should not be used in isolation for clinical decision-making.
What the evidence shows
Recent studies have highlighted the potential of TMB as a predictive biomarker for immunotherapy response. A systematic review by Samstein et al. (2019) analyzed data from over 1,600 patients across multiple cancer types and found that higher TMB was associated with improved overall survival in patients treated with immune checkpoint inhibitors (PMID: 30643254). Similarly, a study by Rizvi et al. (2015) demonstrated that non-small cell lung cancer (NSCLC) patients with high TMB had significantly better responses to pembrolizumab, an anti-PD-1 therapy (PMID: 25765070).
Furthermore, a meta-analysis by Valero et al. (2021) evaluated the predictive value of TMB across different tumor types and confirmed its association with enhanced response rates to immunotherapy (PMID: 33451814). These findings suggest that TMB could serve as a useful tool in stratifying patients for immunotherapy, potentially leading to more personalized treatment approaches.
Caveats and uncertainty
Despite promising results, several caveats and uncertainties remain regarding the use of TMB as a predictive biomarker. One major challenge is the lack of standardized methods for measuring TMB, which can lead to variability in results across different laboratories and studies. Additionally, the threshold for defining "high" TMB is not universally agreed upon, complicating its clinical application.
Moreover, TMB is not the sole determinant of immunotherapy response. Factors such as tumor microenvironment, immune cell infiltration, and other genetic alterations also play critical roles. As such, relying solely on TMB could lead to suboptimal treatment decisions. The predictive value of TMB may also vary depending on the cancer type, as evidenced by mixed results in certain malignancies.
How this may change practice
If validated through further research, TMB could become an integral part of the decision-making process for immunotherapy. It may help oncologists identify patients who are more likely to benefit from immune checkpoint inhibitors, thereby optimizing treatment plans and potentially improving outcomes. However, given the current uncertainties, TMB should be considered alongside other clinical and molecular factors rather than as a standalone biomarker.
Integration of TMB testing into clinical practice would require standardization of measurement techniques and consensus on threshold values. Additionally, ongoing research and clinical trials are essential to refine our understanding of TMB's role in predicting immunotherapy response and to establish its utility across different cancer types.